These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16914882)

  • 1. Alzheimer's disease immunotherapy: from in vitro amyloid immunomodulation to in vivo vaccination.
    Solomon B
    J Alzheimers Dis; 2006; 9(3 Suppl):433-8. PubMed ID: 16914882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease and immunotherapy.
    Solomon B
    Curr Alzheimer Res; 2004 Aug; 1(3):149-63. PubMed ID: 15975063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease.
    Solomon B
    DNA Cell Biol; 2001 Nov; 20(11):697-703. PubMed ID: 11788047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological approaches as therapy for Alzheimer's disease.
    Solomon B
    Expert Opin Biol Ther; 2002 Dec; 2(8):907-17. PubMed ID: 12517269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological approach for the treatment of Alzheimer's disease.
    Solomon B
    J Mol Neurosci; 2003; 20(3):283-6. PubMed ID: 14501009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-amyloidbased immunotherapy as a treatment of Alzheimers disease.
    Solomon B
    Drugs Today (Barc); 2007 May; 43(5):333-42. PubMed ID: 17724499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for Alzheimer's disease.
    Steinitz M
    Immunotherapy; 2009 May; 1(3):461-9. PubMed ID: 20635962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.
    Wang HC; Yu YZ; Liu S; Zhao M; Xu Q
    Vaccine; 2016 Apr; 34(15):1758-66. PubMed ID: 26945100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
    Pradier L; Blanchard-Brégeon V; Bohme A; Debeir T; Menager J; Benoit P; Barneoud P; Taupin V; Bertrand P; Dugay P; Cameron B; Shi Y; Naimi S; Duchesne M; Gagnaire M; Weeden T; Travaline T; Reczek D; Khiroug L; Slaoui M; Brunel P; Fukuyama H; Ravetch J; Canton T; Cohen C
    Alzheimers Res Ther; 2018 Nov; 10(1):117. PubMed ID: 30486882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for Alzheimer's disease.
    Solomon B; Frenkel D
    Neuropharmacology; 2010; 59(4-5):303-9. PubMed ID: 20388523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer's Disease Model Mice.
    Li G; Hu ZW; Chen PG; Sun ZY; Chen YX; Zhao YF; Li YM
    ACS Chem Neurosci; 2017 Mar; 8(3):454-459. PubMed ID: 28292186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological approaches for amyloid-beta clearance toward treatment for Alzheimer's disease.
    Solomon B
    Rejuvenation Res; 2008 Apr; 11(2):349-57. PubMed ID: 18341423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunotherapy of Alzheimer's disease. Results of experimental investigations and treatment of perspectives].
    Karkos J
    Fortschr Neurol Psychiatr; 2004 Apr; 72(4):204-19. PubMed ID: 15095177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
    Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
    Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined treatment of amyloid-β₁₋₄₂-stimulated bone marrow-derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APPswe/PSENldE9 mice.
    Wang F; Liu H; Shen X; Ao H; Moore N; Gao L; Chen L; Hu H; Ma H; Yang Z; Zhai C; Qin J; Zhou G; Peng Y; Feng X; Li R; Liang C
    Neurobiol Aging; 2015 Jan; 36(1):111-22. PubMed ID: 25085784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
    Menéndez-González M; Pérez-Piñera P; Martínez-Rivera M; Muñiz AL; Vega JA
    Curr Pharm Des; 2011; 17(5):508-20. PubMed ID: 21375481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
    Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
    Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-mediated immunotherapy for Alzheimer's disease.
    Solomon B
    Curr Opin Investig Drugs; 2007 Jul; 8(7):519-24. PubMed ID: 17659471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.